Pradas-VelascoRAntonanzas-VillarFMartinez-ZarateMP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics. 2008;26(1):45–56.
2.
WhiteTLavoieSNettlemanMD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics. 1999;103(6):e73.
3.
CohenGMNettlemanMD. Economic impact of influenza vaccination in preschool children. Pediatrics. 2000;106(5):973–6.
4.
LuceBRZangwillKMPalmerCS. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics. 2001;108(2):E24.
5.
RothbergMBRoseDN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med. 2005;118(1):68–77.
6.
TurnerDAWailooAJCooperNJSuttonAJAbramsKRNicholsonKG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2006;24(7):1035–43.
7.
ProsserLABridgesCBUyekiTM. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12(10):1548–58.
8.
ProsserLAO’BrienMAMolinariNA. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics. 2008;26(2):163–78.
9.
AndersonRMMayRM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press; 1991.
10.
BridgesCBFukudaKUyekiTMCoxNJSingletonJA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002;51(RR-3):1–31.
ChowellGMillerMAViboudC. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect. 2008;136(6):852–64.
13.
RussellLBGoldMRSiegelJEDanielsNWeinsteinMC. The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(14):1172–7.
14.
KhazeniNHuttonDWGarberAMHupertNOwensDK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009;151(12):829–39.
15.
LeeBYBaconKMDonohueJMWiringaAEBaileyRRZimmermanRK. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine. 2011;29(11):2149–58.
US Department of Labor, Bureau of Labor and Statistics. Consumer price index: detailed report. Available from: http://www.bls.gov/cpi/#tables
18.
GoldieSJKimSY. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191–215.
19.
LugnerAKMyliusSDWallingaJ. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ. 2010;19(5):518–31.
20.
BergmanAHjelmgrenJOrtqvistA. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40(9):721–9.
21.
IsaacmanDJStruttonDRKalpasEA. The impact of indirect (Herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther. 2008;30(2):341–57.
22.
LloydAPatelNScottDARungeCClaesCRoseM. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ. 2008;9(1):7–15.
23.
VespaGConstenlaDOPepeC. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publica. 2009;26(6):518–28.
24.
RozenbaumMHHoekAJHakEPostmaMJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine. 2010;28(12):2367–9.
25.
JohnsBBaltussenR. Accounting for the cost of scaling-up health interventions. Health Econ. 2004;13(11):1117–24.
26.
JohnsBTorresTT. Costs of scaling up health interventions: a systematic review. Health Policy Plan. 2005;20(1):1–13.
27.
LonginiIMJrHalloranMENizamAYangY. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159(7):623–33.
28.
TurnerDWailooANicholsonKCooperNSuttonAAbramsK. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7(35):iii–iv, xi–xiii, 1–170.
29.
MeltzerMICoxNJFukudaK. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5(5):659–71.
